The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kolina I.B.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka

Stavrovskaia E.V.

Kafedra nefrologii i gemodializa FPPOV Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Efficiency and safety of lipid-lowering therapy for chronic kidney disease

Authors:

Kolina I.B., Stavrovskaia E.V.

More about the authors

Journal: Therapeutic Archive. 2013;85(6): 73‑77

Read: 7392 times

Contact the author
Table of contents

EFFICIENCY AND SAFETY OF LIPID-LOWERING THERAPY FOR CHRONIC KIDNEY DISEASE
EFFICIENCY AND SAFETY OF LIPID-LOWERING THERAPY FOR CHRONIC KIDNEY DISEASE

To cite this article:

Kolina IB, Stavrovskaia EV. Efficiency and safety of lipid-lowering therapy for chronic kidney disease. Therapeutic Archive. 2013;85(6):73‑77. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A review of the recent clinical studies on the treatment of patients with the chro­nic kidney disease et adva­nced stages. Russian Journal of Preventive Medi­cine. 2025;(8):110-114
Chro­nic kidney disease and microcirculation diso­rders. Russian Journal of Preventive Medi­cine. 2025;(8):123-130
Economics of hype­rparathyroidism. Part 2 — seco­ndary hype­rparathyroidism. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):74-82
Recu­rrent coro­nary events as a persistent challenge in cardiology. The role of PCSK9 inhi­bitors in respect of this issue through the example of a local program implemented in St. Pete­rsburg. Russian Journal of Preventive Medi­cine. 2025;(9):78-86
Practical reco­mmendations for the sudden cardiac death prevention among vehi­cle drivers. Russian Journal of Preventive Medi­cine. 2026;(3):86-93
Clinical expe­rience of switching between PCSK9-targeted drugs: effect on lipid para­meters and frequency of achievement of therapeutic goals. Russian Journal of Cardiology and Cardiovascular Surgery. 2026;(2):58-64
A case report of successful pregnancy and childbirth in a patient with kidney transplant. Russian Bulletin of Obstetrician-Gynecologist. 2026;(2):53-57
Asse­ssment of the high-intensity statin therapy impact on the inci­dence of recu­rrent myocardial infa­rction in patients at the high cardiovascular risk. Russian Journal of Preventive Medi­cine. 2026;(5):67-72
Chro­nic kidney disease during pregnancy: problems of primary diagnosis and possibilities of ultrasound screening. Russian Bulletin of Obstetrician-Gynecologist. 2026;(3):80-87
Iron defi­ciency in patients with the chro­nic kidney disease: frequency and clinical-prognostic aspe­cts. Russian Journal of Preventive Medi­cine. 2026;(6):76-84
Abstract:

The paper considers the problem of lipid-lowering therapy for chronic kidney disease, by using different groups of drugs, the expediency, efficiency, and safety of the therapy at different disease stages, including end-stage renal failure, and replacement treatments.

Keywords:

chronic kidney disease
lipid-lowering treatment

Authors:

Kolina I.B.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka

Stavrovskaia E.V.

Kafedra nefrologii i gemodializa FPPOV Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Close metadata

References:

  1. Hostetter T.H. Chronic Kidney Disease Predicts Cardiovascular Disease. N Engl J Med 2004; 351: 1344-1346.
  2. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97.
  3. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences Am J Physiol Ren Physiol 2005; 290: F262-F272.
  4. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269.
  5. Schaeffner S., Kurth T., Curhan G.C. et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084- 2091.
  6. Muntner P., Coresh J., Smith J.C. et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301.
  7. Chen J., Muntner P., Hamm L.L. et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140 (3): 167.
  8. Tanaka H., Shiohira Y., Uezu Y. et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69 (2): 369-374.
  9. Kopple J.D., Feroze U. The effect of obesity on chronic kidney disease. J Ren Nutr 2011; 1 (1): 66-71.
  10. Kolina I.B. Vliyanie narushenii lipidnogo obmena na techenie i prognoz khronicheskogo glomerulonefrita s nefroticheskim sindromom: Dis. ... kand. med. nauk. M 2002.
  11. Wanner C., Krane V., Marz W. et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353 (3): 238-248.
  12. Fellstrom B.C., Jardine A.G., Schmieder R.E. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360 (14): 1395-1407.
  13. Strippoli G.F.M., Navaneethan S.D., Johnson D. et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 336 (7645): 645-651.
  14. Shiomi M., Ito T., Tsukada T. et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerotic mature WHHL rabbits. Arterioscl Thromb Vase Biol 1995; 15: 1938-1944.
  15. Crisby M., Nordin-Fredriksson G., Shah P.K. et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
  16. Muntner P., He J., Astor B.C. et al. Traditional and nontraditional risk factors predict soronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005; 16: 529-538.
  17. Douglas K., O'Malley P.G., Jackson J.L. Meta-Analysis: The Effect of Statins on Albuminuria. Ann Intern Med 2006; 145: 117-124.
  18. Palinski W. Immunomodulation: a new role for statins? Nature Med 2000; 12: 1311-1312.
  19. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983-984.
  20. Zelvyte I., Dominaitiene R., Crisby M., Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002; 45 (2): 147-154.
  21. Kolina I.B., Stavrovskaya E.V., Shilov E.M. Materia Medica 2003; 37 (1): 31.
  22. Kasiske B.L., Wanner C., O'Neill W.Ch. An Assessment of Statin Safety by Nephrologists. Am J Cardiol 2006; 97 (8A): 82S-85S.
  23. Laaksonen R., Tarasov K., Kauhanen D. et al. Plasma Eicosanoids are Potential Biomarkers for Muscle Weakness and Pain related to Statin Treatment. Circulation 2011; 124: A14888.
  24. Chapman M.J. Pharmacology of fenofibrate. Am J Med 1987; 83: 21-25.
  25. Davidson M. H., Armani A., McKenney J.M., Jacobson T. A. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99: 3-18.
  26. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 2: 353-361.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.